The Hair Loss Screening Study

Currently Recruiting

$200

This pre-screening study is designed to identify healthy individuals with androgenetic alopecia (AGA) who may be eligible to take part in future clinical trials investigating new treatments for this condition. Participation in this pre-screening does not guarantee enrolment in a clinical trial, but it is an important first step in determining your suitability.

By taking part, you’ll be contributing to research that aims to improve treatment options for people living with AGA.

Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions.

Apply now Speak with us

Join our clinical trial

We’re currently seeking participants for a clinical trial investigating Androgenetic Alopecia (AGA)—commonly known as pattern hair loss.

You do not need a formal AGA diagnosis to attend. If you suspect you have AGA, you’re welcome to screen, as long as you meet the other eligibility criteria.

Why participate?

Hair loss is common, affecting both men and women. These clinical studies aim to explore new approaches that may support future treatment options. While the main goal is to understand safety and tolerability, your participation helps shape the future of hair loss research. 

Trial details

Additional eligibility

You may be eligible if you:

  • Weigh over 60kg.
  • Are experiencing male or female pattern hair loss  
  • Men: thinning at the crown or a receding hairline  
  • Have had hair loss for 12 months or more 
  • Are not experiencing sudden or unexplained shedding

You won’t be eligible if you:

  • Have hormone-related conditions like hyperprolactinemia or prolactinoma
  • Used hormone replacement therapy (HRT) in the 6 months before screening
  • Have ever had:
    • A hair transplant
    • Microneedling, laser, or surgical scalp treatments
  • Have any other scalp conditions besides AGA, including:
    • Alopecia areata
    • Scarring hair loss (e.g. lichen planopilaris, folliculitis decalvans)
    • Lupus, psoriasis, or severe dandruff affecting the scalp
    • Fungal or active scalp infections
    • Any other inflammatory or scarring scalp condition

Study duration

1 pre-screening call and 1 clinic visit

Are you a match?

Age

18 - 32 years old

Remuneration

$200 *with screening reimbursement. Please see T&Cs.

Gender

Male

BMI

BMI 18 - 32 kg/m2

Commitment

1 clinic visit

Medical condition

Not taking any medications

Register Your Interest for The Hair Loss Screening Study

Find out if you’re eligible to join an upcoming clinical study focused on male pattern hair loss (androgenetic alopecia).

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733 or schedule a call.


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg





















Step 2 of 3
Medical History

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow participants who are (social) smokers.

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Requirements







Referral Information



Consent to Information Use and Future Contact